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ABSTRACT
The demonstration that ovarian carcinoma (OC) is an immunogenic disease, 
opens opportunities to explore immunotherapeutic interventions to improve clinical 
outcome. In this regard, NK cell based immunotherapy could be promising as it has 
been demonstrated that OC cells are susceptible to killing by cytokine-stimulated 
NK cells. Here, we evaluated whether percentage, phenotype, function and IL-15 
responsiveness of ascites-derived natural killer (NK) cells is related to progression-
free survival (PFS) and overall survival (OS) of advanced stage OC patients. Generally, 
a lower percentage of NK cells within the lymphocyte fraction was seen in OC ascites 
(mean 17.4 ± 2.7%) versus benign peritoneal fluids (48.1 ± 6.8%; p < 0.0001). 
Importantly, a higher CD56+ NK cell percentage in ascites was associated with a 
better PFS (p = 0.01) and OS (p = 0.002) in OC patients. Furthermore, the functionality 
of ascites-derived NK cells in terms of CD107a/IFN-γ activity was comparable to that 
of healthy donor peripheral blood NK cells, and stimulation with monomeric IL-15 or 
IL-15 superagonist ALT-803 potently improved their reactivity towards tumor cells. By 
showing that a higher NK cell percentage is related to better outcome in OC patients 
and NK cell functionality can be boosted by IL-15 receptor stimulation, a part of NK 
cell immunity in OC is further deciphered to exploit NK cell based immunotherapy.
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INTRODUCTION
Because ovarian carcinoma (OC) is generally 
asymptomatic until ascites or metastases beyond the 
ovaries have developed, patients are often diagnosed in 
advanced stage. Moreover, the presence and progression 
of ascites is associated with dismal prognosis and poor 
quality of life [1]. Current therapy consists of debulking 
surgery combined with platinum/taxane chemotherapy, 
but the majority of patients develop a recurrence within 3 
years. Especially, for women with advanced stage disease 
the prognosis is dismal, and despite therapeutic advances 
the 5-year survival is only 28% [2].
Since many studies demonstrated that OC is 
an immunogenic disease, further research is needed 
to explore the opportunities of immunotherapeutic 
interventions to improve clinical outcome. In this regard, 
OC ascites is an attractive source to study immune cell 
function in patients because tumor cells and immune cells 
are both present. Furthermore, ascites contains a variety of 
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immunosuppressive cellular and soluble components that 
influence the function of tumor-targeting lymphocytes 
[3–8]. Several studies showed that presence of tumor-
infiltrating lymphocytes positively correlated with survival 
in cancer patients [9–16]. While the importance of CD8+ 
T cell infiltration has been clearly demonstrated, the role 
of infiltrating innate natural killer (NK) cells remains 
unclear. Interestingly, it was reported that CD103+ 
tumor-infiltrating NK cells often co-infiltrate with 
CD8+CD103+ T cells, yet the contribution of NK cells to 
improving outcome is difficult to assess [11]. Therefore, 
more research is required to decipher the role of NK cell 
immunity in OC patients.
NK cells are activated against neoplastic cells 
through a balance of activating and inhibitory receptors 
[17, 18]. Epidemiological research has shown that low 
NK cell activity is associated with increased cancer risk 
in humans [19]. For OC patients, decreased functionality 
of ascites-derived NK cells has been observed [20], 
which could be partially attributed to the low expression 
of various activating NK cell receptors including CD16, 
DNAM-1 and NKp30 [8, 21, 22]. Similarly, ascites-
derived T cells are rather inactive, though proliferation 
and functionality can be partially restored by cytokine 
stimulation [23]. NK cells from ascites also exhibit low 
cytotoxic efficacy, which could be reinvigorated by IL-2 or 
IL-15 [24]. In this regard, Felices et al. recently reported 
that the, ALT-803, a fusion protein complex of IL-15 
variant (N72D) bound to sushi domain of IL-15Rα fused 
to IgG1 Fc, potently enhanced the function of ascites-
derived NK cells and healthy donor peripheral blood 
NK cells exposed to ascites fluid [25]. Most importantly, 
many studies demonstrated that OC cells are susceptible to 
killing by cytokine-stimulated NK cells [26–41]. 
In this study, we characterized NK cell percentage, 
phenotype and functionality in ascites of advanced OC 
patients in relation to clinical outcome, and investigated 
their responsiveness to IL-15 receptor mediated 
stimulation. We observed that a higher CD56+ NK cell 
proportion within the ascites lymphocyte fraction was 
associated with better progression free survival (PFS; 
p = 0.01) and overall survival (OS; p = 0.002) in OC 
patients. Furthermore, we demonstrated that the cytolytic 
function of ascites-derived NK cells can be effectively 
reinvigorated with either monomeric IL-15 or the IL-15 
superagonist fusion complex, ALT-803. These findings 
indicate that boosting NK cell expansion and functionality 
by immunotherapeutic strategies could improve survival 
in OC patients.
RESULTS
Patient cohort characteristics
For this study, we selected ascites fluid samples 
collected at diagnosis or first surgery of patients with stage 
IIIc or IV high-grade serous papillary OC. The mean age 
of the selected OC patient cohort (n = 20) was 64 ± 8.8 
years and 48 ± 8.1 years for the benign gynecological 
disorder control group (n = 10). The median OS and PFS 
of the OC patient cohort at time of analysis was 19 months 
and 6 months, respectively. Based on the median OS, the 
patient cohort was divided in two groups: i.e. poor survival 
group (n = 10) with an OS of less than 19 months and good 
survival group (n = 10) with an OS of more than 19 months 
(Table 1). The OS and PFS in the good survival group 
were 32.9 ± 11.2 and 19.7 ± 16.4 months, respectively. 
Whereas the OS and PFS in the poor survival group was 
only 10.3 ± 4.4 and 3.2 ± 2.3 months, respectively. Further 
characteristics of the two OC patient groups are shown in 
Table 1. Patients in the good survival group were younger 
and were less often postmenopausal. In both groups, half 
of the OC patients were treated with primary surgery, and 
half with neo-adjuvant chemotherapy. CA-125 levels were 
higher in the good survival group.
High peritoneal NK cell proportion within the 
lymphocyte fraction is associated with better 
survival of OC patients
First, we assessed the percentages of NK, NKT and 
T cells within the lymphocyte fraction in cryopreserved 
ascites samples of the selected OC patients by flow 
cytometry and compared those with peritoneal fluid of 
10 patients with a benign gynecological disorder. Within 
the total cell fraction OC ascites contained 38.8 ± 24.8% 
lymphocytes, 40.5 ± 24.7% CD45+ non-lymphocytes 
and 16.4 ± 23.5% CD45- non-hematopoietic tumor 
cells, and the benign samples contained 58.7 ± 40.4% 
lymphocytes and 36.5 ± 34.1% non-lymphocytes within 
CD45+ leucocytes (Figure 1A). Within the lymphocytes 
a significantly lower CD3-CD56+ NK cell percentage 
was seen in OC patient ascites (mean 17.1 ± 2.7%) 
compared to benign peritoneal fluid (48.1 ± 6.8%, 
p < 0.0001; Figure 1B). Furthermore, lower CD3+ T cell 
and CD3+CD56+ NKT cell percentages were observed 
within the lymphocyte population in OC patient ascites. 
The population of non T-, non-NKT, non-NK cells in the 
lymphocyte gate, presumably B cells, was more prominent 
in the malignant samples (Figure 1B). Notably, the group 
of OC patients with poor survival had 14.5 ± 3.6% NK 
cells versus 23.6 ± 4.0% in the patients with good survival 
(Figure 1C). In addition, we observed a significant shift 
in the CD56dim/bright ratio in OC patients in comparison to 
peritoneal fluid of patients with a benign gynecological 
disorder (Figure 1D). Generally, in healthy donor blood 
around 90% cytotoxic CD56dim and 10% regulatory 
CD56bright cells are present [42]. In contrast, in the benign 
ascites samples we found 32.4 ± 3.7% NKdim cells and 67.5 
± 3.7% CD56bright cells, respectively. In OC patient ascites, 
however, the ratio was more in favor of the cytotoxic 
CD56dim population with 54.7 ± 4.0% CD56dim and 
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45.4 ± 4.0% CD56bright cells, compared to the benign 
peritoneal fluids (Figure 1D).
Next, we divided the OC patients in two groups 
based on the median ascites NK cell percentage within 
the lymphocyte fraction into high (mean 31.4 ± 9.4%) and 
low (mean 8.9 ± 4.6%) percentage groups. We observed 
that both OS (p = 0.002, hazard ratio = 5.7) and PFS 
(p = 0.01, hazard ratio = 4.7) were significantly better in 
OC patients with a high peritoneal NK cell percentage 
versus patients with a low NK cell percentage in the 
lymphocyte fraction (Figure 1E and 1G). Notably, this 
relationship was not observed for CD3+ T cell percentages 
in ascites (Figure 1F and 1H). Interestingly, in the high 
NK group three patients are still alive after a follow-up 
of ≥50 months. Altogether, these data indicate that the 
CD56+ NK cell percentage within the lymphocyte fraction 
in ascites fluid of OC patients is positively correlated with 
clinical outcome.
Ascites-derived NK cells of poor survival ovarian 
carcinoma patients exhibit low expression levels 
of activating receptors
Next to the percentage of NK cells in ascites, we 
studied whether survival of OC patients was associated 
with differential expression of NK cell activating 
receptors. Hereto, we performed flow cytometry analysis 
on the ascites-derived NK cells of the selected patient 
cohort and benign ascites controls (Figure 2). While 2B4 
had equally high positivity on both benign and malignant 
peritoneal fluid NK cells, NKG2D was low to undetectable 
on these NK cells. Remarkably, NKp30 was almost absent 
on NK cells in malignant samples (mean 3%), whereas 
it was significantly higher on NK cells from benign 
samples (mean 79%). NKG2A can suppress activation, 
and shows no significant differences between benign and 
malignant samples. Moreover, NKp46 and DNAM-1 were 
significantly lower expressed on NK cells in malignant 
samples, especially in patients with a poor OS. Together, 
these data indicate that ascites NK cells of OC patients 
with poor survival have significantly lower expression of 
activation receptors on their surface.
Ascites-derived NK cells possess equal cytotoxic 
function as peripheral blood NK cells from 
healthy donors
Next, we addressed the functional activity of 
peritoneal fluid NK cells of OC patients in comparison 
to peripheral blood (PB)-NK cells from healthy donors. 
Here, we cultured MNCs from ascites of OC patients or 
PB of healthy controls overnight in the presence of IL-15, 
whereupon total cells were challenged for 4 hours with 
either K562 (control), SKOV-3 OC or without tumor 
cells and subsequently analyzed by flow cytometry. We 
examined expression of the activation markers CD69 and 
TRAIL, the degranulation of NK cells using CD107a, and 
intracellular IFN-γ positivity. Both ascites and control 
NK cells showed high CD69 expression, while TRAIL 
levels decreased upon tumor challenge (Figure 3A 
and 3B). Furthermore, ascites-derived NK cells were 
capable of exerting a CD107a degranulation and IFN-γ 
response against K562 cells (Figure 3C and 3D). However, 
reactivity of ascites-derived NK cells greatly varied 
between different OC patients, therefore no significant 
differences were observed as compared to healthy donor 
NK cells. Notably, for both OC ascites and healthy donor 
NK cells the response against SKOV-3 OC cells was 
poor. Together, these data demonstrate that OC ascites-
derived NK cells have equivalent degranulation and 
IFN-γ secretion capacity as healthy donor PB-NK cells, 
yet responsiveness against SKOV-3 OC cells is limited.
Functionality of ascites NK cells can be 
effectively boosted by IL-15 or ALT-803 
stimulation
To improve peritoneal NK cell reactivity against 
OC, we investigated whether boosting with monomeric 
recombinant human IL-15 or the human IL-15 superagonist 
Table 1: Patient characteristics
Characteristics Good survival (n = 10) Poor survival (n = 10)
Baseline Age mean (SD) 57.2 (8.4) 69.0 (11.4)
CA-125 mean (95% CI) 1532 (641–2423) 1268 (199–2337)
Postmenopausal 70% 90%
Treatment Neoadjuvant Chemotherapy 50% 60%
Primary surgery 50% 40%
Debulking Complete Debulking 20% 20%
(Sub-) Optimal Debulking 80% 70%
No Debulking 0% 10%
Survival PFS mean (SD) 19.7 (16.4) 3.2 (2.3)
OS mean (SD) 32.9 (11.2) 10.3 (4.4)
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Figure 1: NK, NKT and T cell percentage in benign ascites and ascites from ovarian cancer patients. (A) Fraction 
of CD45+ lymphocytes (white), CD45+ non-lymphocytes (grey) and CD45- cells (black) cell populations within peritoneal fluid of 
benign compared to malignant ovarian cancer patients, based on flow cytometric analysis of CD45 expression and forward/side scatter. 
(B) Percentage of NK cells, T cells, NKT cells and other lymphocytes within benign and malignant ascites. The percentage NK cells within 
the lymphocyte population is significantly different, two tailed T-test p < 0.0001. (C) Within the lymphocyte population the percentage of 
NK cells is depicted. The group of malignant ovarian carcinoma ascites patients is divided into good and poor survival based on the median 
survival of the analyzed patient cohort (n = 20). (D) The NK cell population is subdivided based on CD56 bright and CD56 dim cells. 
(E) Overall survival curve of OC patients groups with low and high CD56+ NK cell percentages in ascites. (F) Overall survival curve of 
OC patients groups with low and high CD3+ T cell percentages in ascites. (G–H) Progression free survival curves for low and high CD56+ 
NK cell and CD3+ T cell percentages in ascites. Error bars represent mean + SEM. When 2 groups were compared the Student T-test was 
used whereas a one-way ANOVA with Bonferroni correction was performed when comparing 3 groups. ***p = 0.001.
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fusion complex, ALT-803. Interestingly, IL-15 receptor-
mediated stimulation already enhanced CD107a expression 
and IFN-γ secretion capacity of the NK cells in the absence 
of tumor challenge (Figure 4A and 4D). Most importantly, 
ascites-derived NK responsiveness against K562 and 
especially SKOV-3 OC cells could be potently augmented 
by IL-15 or ALT-803 stimulation (p < 0.001 for CD107a 
and p < 0.01 for IFN-γ; Figure 4B, 4C, 4E and 4F). These 
data demonstrate that the function activation of NK cells in 
ascites can be efficiently rescued with IL-15 or ALT-803.
DISCUSSION
NK cells are activated against cancer cells via 
activating and inhibitory receptors, and the balance in 
these signals determines the magnitude of their activity. 
[17, 18] Epidemiological research has shown that low NK 
cell activity is associated with increased cancer risk in 
humans [19]. Moreover, NK cells have been identified to 
play a role in tumor surveillance due to enhanced surface 
expression of ligands for activating receptors on tumor 
cells by the DNA damage response [43]. Together these 
studies underscore the contribution of NK cell function 
in anti-cancer immunity. However, there is limited data 
on the contribution of NK cell immunity on the clinical 
outcome of women with ovarian carcinoma. In the present 
study, we found that the percentage of CD56+ NK cells 
within the lymphocyte fraction in ascites fluid is related to 
OS and PFS, and that ascites-derived NK cells have lower 
expression of activation markers than benign peritoneal 
fluid NK cells. Although, ascites-resident NK cells have 
poor reactivity against SKOV-3 OC cells (similarly as 
PB-NK cells) they can be effectively boosted by IL-15 
receptor mediated stimulation. 
Figure 2: Expression of activating receptors on CD45+CD3-CD56+ NK cells. Percentage positive 2B4, NKG2D, NKp46, 
NKp30, DNAM-1 and NKG2A NK cells of CD56+ NK cells in benign and malignant peritoneal fluid. The group of malignant ovarian 
carcinoma ascites patients is divided into lower than median overall survival and higher than median overall survival. Error bars represent 
mean + SEM. One way ANOVA with Bonferroni correction was performed when comparing the groups. *= p < 0.05, ***= p < 0.001.
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In our current study, OC patients were randomly 
selected from our ascites biobank. Nevertheless, as large 
amounts of ascites MNCs was required for these studies, 
we thereby selected automatically a group of patients with 
a relatively poor prognosis. A remarkably high percentage 
of these patients did not undergo complete debulking 
surgery, however since rates of complete debulking were 
comparable in both the poor and good OS groups, we 
believe that the impact of incomplete debulking on our 
NK cell correlative results is limited. Notably, the OS of 
our patient cohort is comparable to a large national cohort 
[44]. Although there were age differences between the 
benign control and the OC groups we do not expect impact 
on our findings, as it has been reported for PB that NK 
cell percentages are very stable and do not change with 
age [45]. 
Notably, a higher NK cell percentage within the 
lymphocyte fraction was found in peritoneal fluid of 
benign control subjects than in ascites of OC patients. 
Often peritoneal fluid of healthy individuals is used 
in endometriosis research, and also in this disease a 
significantly lower percentage of NK cells in peritoneal 
fluid has been reported [46]. In OC the only relation 
between clinical outcome and NK cells in ascites was 
described by Dong et al., and they reported CD16 positive 
cells to be associated with poorer outcome of OC patients. 
Unfortunately, CD56 expression was not evaluated in 
their report [12]. Our paper is the first report to show a 
relationship between the CD56+ NK cell proportion 
within the ascites lymphocyte fraction and clinical 
outcome parameters. While the importance of CD8+ 
T cell infiltration within OC tumors has been clearly 
demonstrated, and also CD3+ T cells in ascites have been 
found to correlate with better outcome [47, 48], a relation 
between CD3+ T cell percentage and survival was not 
observed in our cohort. Besides percentages, absolute 
numbers of infiltrating lymphocytes is an important 
parameter for correlation with clinical outcome. However, 
as volume and cellular density in ascites differed greatly 
between OC patients, we believe that the percentage 
within the lymphocyte population was the most objective 
way to compare cell populations. For future research, 
it would be interesting to investigate how ascites NK 
cells differ from blood NK cell numbers, phenotype and 
function in the same OC patient.
It has been previously reported that OC ascites NK 
cells have been described to exhibit lower expression 
of the activating markers NKp30, NKp46, NKG2D and 
DNAM-1 compared to healthy donor PB-NK cells [8, 
49]. In our study, we observed the same significantly 
lower expression of NKp30, NKp46 and DNAM-1 on 
OC ascites-derived NK cells compared to NK cells 
from benign peritoneal fluid. However, the relationship 
between NKG2D and prognosis was not found in our 
dataset. Interestingly, we observed a significant lower 
NK cell expression of NKp30 in poor prognosis versus 
good prognosis ascites samples, suggesting that NKp30 
expression changes in the poor prognosis OC environment. 
The same has been reported in acute myeloid leukemia, 
where NKp30 is proposed as a prognostic biomarker 
based on its low expression on NK cells in poor prognosis 
patients [50]. Further validation in a larger patient cohort 
is required to establish prognostic biomarkers in OC 
patients.
In our functional studies, ascites-derived NK cells 
demonstrated equal degranulation and cytokine secretion 
potential as healthy donor PB-NK cells. This corresponds 
with findings by Felices et al. who showed comparable levels 
of CD107a after stimulation in the presence or absence of 
tumor cells [25]. In contrast, other reports demonstrated that 
Figure 3: Degranulation assay comparing NK cells in healthy donor (HD) peripheral blood mononuclear cells (PBMCs) 
with ascites mononuclear cells (MNCs). Percentage CD56+ NK cells positive for (A) CD69, (B) TRAIL, (C) CD107a, (D) IFN-γ, 
after 4 h stimulation with no target cells, K562 or SKOV-3 tumor cells. Error bars represent mean + SEM. Open symbols depict HD 
PBMCs, closed symbols depict ascites MNCs. One way ANOVA with Bonferroni correction was performed when comparing the groups.
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ascites-derived NK cells were dysfunctional, with decreased 
CD16 expression and low cytotoxic capacity [6, 51, 52]. 
Here, we showed that ascites-derived NK cells were highly 
capable of recognizing K562 tumor cells, but exhibited 
poor SKOV-3 OC cell reactivity. Most importantly, we 
demonstrated that stimulation with IL-15 or ALT-803 could 
reinvigorate NK cell degranulation and IFN-γ production, 
especially against SKOV-3 OC cells. Although our ex vivo 
studies did not show any difference between IL-15 and ALT-
803, ALT-803 is likely more potent in long-term assays and 
in vivo because of its longer half-life [53, 54].
Concluding, this report shows a significant 
association between the percentage and phenotype of NK 
cells within the lymphocyte fraction in peritoneal fluid 
and survival of OC patients. Moreover, we demonstrated 
that peritoneal NK cell reactivity against OC tumor cells 
can be efficiently boosted by IL-15 receptor-mediated 
stimulation. The relationship between availability of 
NK cells in the abdominal cavity and the potentiating 
effect of IL-15 indicates that intraperitoneal NK cell 
adoptive transfer combined with IL-15 administration 
could be an interesting new therapy for OC patients 
to improve outcome. Currently, a phase 1 clinical trial 
testing intraperitoneal ALT-803 therapy in OC patients is 
enrolling patients in the US (NCT0354909) and a phase 1 
clinical trial on intraperitoneal NK cell therapy exploiting 
CD34+ progenitor-derived NK cells is open in the 
Netherlands (NCT03539406). By demonstrating that high 
NK cell percentages are associated with better outcome in 
OC patients and peritoneal NK cell functionality can be 
boosted by IL-15 receptor stimulation, a part of NK cell 
immunity in OC is further deciphered to exploit NK cell 
based immunotherapy in these poor prognosis patients.
MATERIALS AND METHODS
Ascites fluid samples were prospectively collected 
at diagnosis or first surgery of patients with stage IIIc 
or IV high-grade serous papillary OC between January 
2009 and January 2013 at the Radboud University 
Medical Center (RUMC). Study approval was given by 
the Regional Committee for Medical Research Ethics 
(CMO 2013-516) and performed according to the Code 
for Proper Secondary Use of Human Tissue (Dutch 
Federation of Biomedical Scientific Societies, www.
federa.org). Ascites was filtered using a 100 µm filter, 
washed and MNCs were isolated by Ficoll-Hypaque 
density gradient centrifugation. Subsequently, obtained 
cells were cryopreserved and stored in liquid nitrogen until 
use. From this biobank we randomly selected ascitic cell 
samples from 20° C patients. For the benign control group, 
samples were collected at benign gynecological surgeries. 
Main indication for diagnostic laparoscopy was abdominal 
pain, samples were included only if pathological findings 
were absent. Detection of cysts, endometriosis and 
adhesions at laparoscopy were exclusion criteria. These 
benign samples were processed and analyzed on the day 
of surgery. Medical records were retrospectively reviewed 
Figure 4: Degranulation assay comparing ascites CD56+ NK cells with and without monomeric IL-15 or ALT-803 
stimulation. (A–C) Percentage CD56+ NK cells positive for CD107a after 4 h co-culture with no stimulation (A), K562 cells (B) or 
SKOV-3 cells (C). (D–F) Percentage CD56+ NK cells positive for IFN-γ after 4 h co-culture with no stimulation (D), K562 cells (E) or 
SKOV-3 cells (F). Error bars represent mean + SEM. One way ANOVA with Bonferroni correction was performed when comparing the 
groups. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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and relevant clinical and pathology data were extracted. 
Time of diagnosis was considered to be the date of the 
primary surgical procedure. Time from diagnosis to death 
was calculated for OS. PFS was calculated as time of last 
chemotherapy till diagnosis of biochemical or radiologic 
recurrence. Median survival was expressed in months.
Patients were divided in groups for Figure 1C and 
Figure 2 based on median overall survival, poor survival 
are the patients with an overall survival of less than the 
median (19 months), good survival are the patients with 
an overall survival of more than 19 months.
For Figure 1E and 1G patients were divided based 
on median NK cell frequency, for Figure 1F and 1H 
groups are divided by median CD3 cell frequency. 
Flow cytometry
MNCs were stained with labeled antibodies, CD3 
ECD (Biolegend), CD45 Krome Orange (R&D systems), 
CD56 PE-Cy5 (Biolegend), CD16 APC-Cy7 (Biologend), 
CD326 PerCPCy5.5 (Biolegend). Phenotypic analysis 
was performed using DNAM-1 FITC (Becton Dickinson), 
2B4 FITC (Biolegend), NKG2A APC (Beckman Coulter), 
NKG2D APC (Biolegend), NKp30 PE (Biolegend) and 
NKp46 PE(Biolegend), isotype controls for IgG1 and 
IgG2a, (all Biolegend). Dead cells were stained with 
1:1000 diluted sytox blue (Life Technologies; Invitrogen). 
Flow cytometry analysis was performed on a Gallios flow 
cytometer from Beckman Coulter. Analysis was done in 
Kaluza 1.5 (Beckman Coulter). Gating strategy is shown 
in Supplementary Figure 1.
K562 and SKOV-3 cell lines
OC cell line SKOV-3 was cultured in Roswell Park 
Memorial Institute medium (RPMI 1640; Gibco) medium 
supplemented with 10% Fetal Calf Serum (FCS; Integro). 
The chronic myeloid leukemia cell line K562 was cultured 
in Iscove’s Modified Dulbecco’s Medium (IMDM) with 
10% FCS.
Functional assay (CD107a and IFN-γ)
After thawing ascites MNCs or PBMCs were 
cultured overnight with 1 nM IL-15 (Immunotools), 1 nM 
ALT-803 (Altor Bioscience) or without cytokine support 
in IMDM with 10% FCS and 1% penicillin/streptomycin 
(p/s). Subsequently, 1 × 106 cells were co-cultured with 
0.5 × 106 K562 cells, 0.5 × 106 SKOV-3 cells or without 
target cells for 4 hours in IMDM with 10% FCS and 1% p/s 
and anti-CD107a PE-Cy7 (Biolegend) in a 24-well plate. 
After 1 h of co-culture, brefeldin A (BD) was added. 
Finally, cells in each well were gently resuspended and 
stained with labeled antibodies, CD56 BV510 (Biolegend), 
CD45 AF700 (Invitrogen), CD3 ECD (Beckman Coulter), 
CD69 BV421 (Biolegend) or isotype IgG1BV421 (BD 
biosciences), and TRAIL APC or isotype IgG1 APC (both 
Biolegend). Dead cells were stained with 1:1000 in PBS 
diluted eFluor780. Next, cells were fixed, permeabilized 
and stained with anti-IFN-γ or isotype IgG1 FITC (BD 
biosciences) and anti-perforin or isotype IgG2b PE 
(Biolegend). Flow cytometry acquisition was performed 
on a Gallios flow cytometer from Beckman Coulter. 
Analysis was done in Kaluza 1.5 (Beckman Coulter). 
Statistical analysis
Statistical analysis was performed in Graphpad 
Prism software package version 5.03. Flow cytometry 
data was expressed as percentage positive cells. Data were 
analyzed using two-way ANOVA for group comparison or 
one-way ANOVA with Bonferroni post-hoc correction if 
more than two groups were compared. Unpaired T-tests 
were performed for comparison of two single groups, as 
indicated. Differences were considered significant when 
the p value was < 0.05. Survival curves were analyzed by 
Log rank (Mantel-Cox) test.
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